Business
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR)...
About this update from Medmira Inc.
[{"type":"text","content":"MedMira Reports FY2025 Fourth Quarter and Year End Financial ResultsHALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2025.Corporate updateIn FY2025, MedMira launched its recently Health Canada approved Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) and its latest generation of its Reveal® Rapid HIV Test in Canada. Subsequent to FY2025, the Company received an additional approval for its Reveal® TP (Syphilis) rapid test by Health Canada. With this approval, the Company launched the fastest Syphilis antibody test available in Canada. With the support of MedMira's partners, provincial validation has been completed and the implementation of the Company's products the various provincial buying groups have commenced. This is a significant step for the Company to offer its products and allow health care professionals to gain access.In the USA, the Company achieved VA and Federal listing that presents a major milestone to gain access to multi-year contracts and awards issued by these organizations. During FY2025, the Company further expanded its distribution network with specialized partners specifically aiming for VA, Federal and States contracts. These achievements enable MedMira to enhance its sales capabilities with established and preferred partners in the USA. Despite certain delays caused with the changing environment in the USA in the first part of the calendar year 2025, there has been a steady progress made in the second part of this year. In FY2025, the Company has been able to bid through its partners on these contracts with its current FDA approved Reveal® G4 HIV-1/2 rapid test and the awards and contract details will be made public when issued by the customers. It is the Company's anticipation with the future FDA CLIA waiver to gain further access to more contracts and further increase the overall sales opportunities.In addition, the Company successfully completed the first phase of the clinical trials in Canada for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). In early December 2025, an independent publication will be issued outlining the performance and positive impact of this product. Subsequent to FY2025, the Company started i...